Article Abstract

Response letter on Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib—new ammunition in battling exon 17 mutations

Authors: Chun-Nan Yeh

Abstract

We thank Eckardt and Klein for their interest in our phase II trial delineating the treatment efficacy of regorafenib in patients with metastatic and/or an unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17 (1). Several issues emerged (2).